登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.gov 上登记的一项胃癌开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07923396,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed unresectable locally advanced or metastatic gastric adenocarcinoma, with no prior systemic therapy for locally advanced or metastatic gastric cancer (including targeted therapy, immunotherapy, and biologic therapy). If neoadjuvant or adjuvant therapy has been received, disease progression or recurrence must have occurred ≥6 months after the completion of neoadjuvant or adjuvant therapy.
入选标准第 3 条
At the time of signing the ICF, toxicities caused by prior antitumor therapy have not recovered to Grade 1 or baseline, except for alopecia and hyperpigmentation (according to NCI-CTCAE version 6.0);
排除标准第 5 条
ECOG performance status of 0 or 1 ;
入选标准第 6 条
At least 1 measurable lesion (according to the RECIST 1.1 criteria);
入选标准第 5 条
A history of other primary malignant tumors within 5 years before study treatment;
排除标准第 11 条
Participants who are positive for hepatitis B surface antigen (HBsAg) at screening must be excluded; if HBsAg is negative but hepatitis B core antibody (HBcAb) is positive, participants with peripheral blood hepatitis B virus (HBV) DNA above the lower limit of detection must be excluded; participants who are positive for hepatitis C virus (HCV) antibody; participants who are positive for human immunodeficiency virus (HIV) antibody; participants who are positive for cytomegalovirus (CMV) DNA; participants who are positive for Treponema pallidum-specific antibody;
排除标准第 19 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07923396,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Understands and voluntarily signs the informed consent form (ICF) before any study-related assessments/procedures are performed; Age ≥18 years at the time of signing the ICF; Histologically confirmed unresectable locally advanced or metastatic gastric adenocarcinoma, with no prior systemic therapy for locally advanced or metastatic gastric cancer (including targeted therapy, immunotherapy, and biologic therapy). If neoadjuvant or adjuvant therapy has been received, disease progression or recurrence must have occurred ≥6 months after the completion of neoadjuvant or adjuvant therapy. At least one lesion ; At least 1 measurable lesion (according to the RECIST 1.1 criteria); ECOG performance status of 0 or 1 ; Expected survival of more than 3 months; Adequate hematologic and organ reserve function;排除标准:Exclusion Criteria:
A history of severe allergy or hypersensitivity to any component of any drug to be used in this study, including but not limited to the planned chemotherapeutic agents and GK01 excipients (e.g., dimethyl sulfoxide); Participation in a clinical trial within 28 days before signing the informed consent form; Receipt of extensive radiotherapy within 28 days before signing the ICF, except for radiotherapy administered locally for symptom relief to non-target lesions within 14 days before signing the ICF or anticipated during the study period; Major surgery within 28 days before signing the ICF (except endoscopic exploration for diagnostic purposes), or major surgery anticipated during the study period; At the time of signing the ICF, toxicities caused by prior antitumor therapy have not recovered to Grade 1 or baseline, except for alopecia and hyperpigmentation (according to NCI-CTCAE version 6.0); Any uncontrolled active infection at the time of signing the ICF or within 4 weeks before the first infusion that requires parenteral antibiotic, antiviral, or antifungal therapy; Active or prior autoimmune disease with the potential for recurrence (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, and psoriasis), or at risk of such disease; A history of prior bone marrow or organ transplantation; Concurrent or prior history of interstitial lung disease or interstitial pneumonitis; A history of active pulmonary tuberculosis infection within 1 year before screening (except for participants with a history of active pulmonary tuberculosis infection more than 1 year previously who, as judged by the investigator, currently have no evidence of active pulmonary tuberculosis); A history of other primary malignant tumors within 5 years before study treatment; Clinically significant cardiovascular disease; A history of bleeding within 6 months before signing the ICF; clinically significant, evident bleeding risk or tendency (any bleeding or bleeding event of Grade ≥3 within 28 days before screening, including esophageal variceal bleeding); Metabolic disorders, such as poorly controlled diabetes mellitus (glycated hemoglobin ≥8.5%), or other non-malignant organ or systemic diseases or secondary reactions to cancer that may result in a higher medical risk and/or uncertainty in the assessment of survival; Central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic central compression; or a prior history of CNS disease, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, and Parkinson disease; Concurrent obstruction; Receipt of a live attenuated/inactivated vaccine within 28 days before signing the ICF, or planned administration of a live attenuated/inactivated vaccine during the screening period; Requirement for systemic corticosteroids (at a dose equivalent to or higher than 10 mg/day prednisone) or other immunosuppressive therapy within 14 days before harvest or during the study; Participants who are positive for hepatitis B surface antigen (HBsAg) at screening must be excluded; if HBsAg is negative but hepatitis B core antibody (HBcAb) is positive, participants with peripheral blood hepatitis B virus (HBV) DNA above the lower limit of detection must be excluded; participants who are positive for hepatitis C virus (HCV) antibody; participants who are positive for human immunodeficiency virus (HIV) antibody; participants who are positive for cytomegalovirus (CMV) DNA; participants who are positive for Treponema pallidum-specific antibody; Complications or other conditions that, in the opinion of the investigator, may affect compliance with the protocol or render the participant unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07923396, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07923396,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。